Opyl is claiming credit for predicting a positive interim outcome of the $DXB/Dimerix ACTION3 Phase 3 trial of DMX-200 in FSGS Kidney Disease.
Bernice Averion, Medtech Marketing Marketing Manager of OPL's TrialKey business:
"...Opyl foresaw this success, predicting a high probability of 74.51% even before the official results were revealed.
"As a result, DXB's share price has experienced a notable surge, underlining the potential benefits of predictive tools like TrialKey for investors.
"Imagine having the foresight to spot viable investments before the market catches on!"
Opyl matters, page-7
Add OPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.6¢ |
Change
-0.004(13.3%) |
Mkt cap ! $4.439M | |||
| Open | High | Low | Value | Volume |
| 2.9¢ | 2.9¢ | 2.6¢ | $5.694K | 212.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300000 | 2.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.6¢ | 1611 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.6¢ |
Change
-0.004 ( 13.3 %) |
||||
| Open | High | Low | Volume | ||
| 2.7¢ | 2.7¢ | 2.6¢ | 158016 | ||
| Last updated 15.44pm 14/06/2024 ? | |||||
| OPL (ASX) Chart |